301 results match your criteria: "Terumo Corporation R & D Center[Affiliation]"
Lung Cancer
January 2025
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML).
Methods: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed.
Effects of the initial peritoneal dialysis (PD) prescription on clinical outcomes are unknown in Japan. We conducted a cohort study using data from Peritoneal Dialysis Outcomes and Practice Patterns Study. The patients were divided into two groups by the volume of the initial PD prescription (≤ 4 L/day or > 4 L/day).
View Article and Find Full Text PDFJACC Cardiovasc Interv
November 2024
Medizinische Klinik und Poliklinik I, University Hospital Munich, Ludwig-Maximilians University, Munich, Germany; Privatklinik Lauterbacher Mühle am Ostsee, Seeshaupt, Germany.
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFRadiology
November 2024
From the Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany (C.C., H.Z., A.U.B., F.P.); NeuroCure Clinical Research Ctr (C.C., H.Z., A.U.B., J.W., F.P.), Dept of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany (C.C.); Medical Image Analysis Center, Basel, Switzerland (V.C.e.S., E.G., D.M.); Paulista School of Medicine, Dept of Neurology and Neurosurgery (D.B.B.), Dept of Diagnostic Imaging, Universidade Federal de São Paulo, São Paulo, Brazil (M.I.I.); Koc Univ, School of Medicine Neurology Dept and Istanbul Univ, Cerrahpasa School of Medicine, Neurology Dept, Istanbul, Turkey (A.A.); Dept of Neurology, Istanbul Univ, Cerrahpasa Faculty of Medicine, Istanbul, Turkey (U.T.); Div of Neurology, Dept of Medicine, Siriraj Hosp, Mahidol Univ, Bangkok, Thailand (S.S.); Bumrungrad International Hosp, Bangkok, Thailand (S.S.); Center for Advanced Neurologic Research, KS Hegde Medical Academy, Nitte Univ, Mangalore, India (L.P., A.D.); Dept of Neurology, Hosp de S. João, Al. Hernâni Monteiro, Porto, Portugal (M.J.S., R.F.); MS Center at Swedish Neuroscience Inst, Seattle, Wash (P.Q., C.T.); Dept of Neurology and Neuroimmunology Clinic, Rabin Medical Center, Petach Tikva, Israel (I.L.); Sackler Faculty of Medicine & Felsenstein Medical Research Center, Tel Aviv Univ, Tel Aviv, Israel (I.L., H.S.K.); Dept of Radiology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (V.K.); Dept of Neurology and Neuroimmunology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (M.A.H.); Neuro-Ophthalmology Div, Dept of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel (H.S.K.); Div of Neurology, Univ of Toronto, St Michael's Hosp, Toronto, Canada (D.L.R., L.W.); Mellen Center, Cleveland Clinic, Cleveland, Ohio (D.O.), Dept of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio (K.N.); Multiple Sclerosis and Neuroimmunology Program, Univ Hosps of Cleveland, Case Western Reserve Univ School of Medicine, Cleveland, Ohio (H.A., M.O.S.); Michigan Inst for Neurologic Disorders, Farmington Hills, Mich (Y.M.D.); Inst of Clinical Neuroimmunology, LMU Hosp, Ludwig-Maximillians Universität München, Munich, Germany (J.H.); Dept of Neurology, Slagelse Hosps, Odense, Denmark (N.A.); Insts of Regional Health Research & Molecular Medicine, Univ of Southern Denmark, Odense, Denmark (N.A.); Dept of Radiology, Aleris Hosp, Copenhagen, Denmark (P.B.S.); NYU Multiple Sclerosis Comprehensive Care Center, Dept of Neurology, NYU School of Medicine, New York, NY (I.K.); Dept of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine Univ Düsseldorf, Düsseldorf, Germany (M.R.); School of Medicine and Dentistry, Gold Coast Campus, Griffith Univ, Queensland, Australia (S.B., S.A.); Dept of Neurology, Gold Coast Univ Hosp, Queensland, Australia (S.A.); Dept of Pediatrics, Univ of Utah, Salt Lake City, Utah (B.M., A.M.J., M.W., S.G., L.J.C.); Dept of Medicine, Divs of Molecular Medicine & Infectious Diseases, and Ludquist Inst for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, Calif (M.R.Y.); Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif (M.R.Y.); Depts of Ophthalmology and Visual Sciences, Kellogg Eye Center, Univ of Michigan, Ann Arbor, Mich (T.J.S.); Div of Metabolism, Endocrine and Diabetes, Dept of Internal Medicine, Univ of Michigan Medical School, Ann Arbor, Mich (T.J.S.); Hoffmann-LaRoche, Basel, Switzerland (J.W.); Dept of Neurology, Charité-Universitätsmedizin Berlin, Germany (F.P.); Affiliated author members of the Guthy-Jackson Charitable Foundation (GJCF) International Clinical Consortium (ICC) for NMOSD are listed in Appendix S1.
Front Cardiovasc Med
October 2024
Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States.
Introduction: Birefringent crystals such as monosodium-urate (MSU) and cholesterol crystals (CC) likely contribute to the progression of coronary artery disease (CAD) due to their potential to exacerbate inflammation through inflammatory cytokine activation. Here, we present cross-polarized micro-optical coherence tomography (CP-µOCT) for visualizing individual birefringent crystals in human coronary arteries.
Methods And Results: Human cadaver coronary arteries with a history of CAD with or without gout were dissected for CP-µOCT imaging.
JMA J
October 2024
Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, Japan.
Introduction: This study investigated the relationships between changes in renal prognosis-related factors after initiating tofogliflozin and the corresponding baseline values in clinical practice in Japanese patients with type 2 diabetes.
Methods: We investigated the relationships between changes in hematocrit, hemoglobin, systolic blood pressure (sBP), urinary protein excretion (uPE), serum uric acid (sUA), and estimated glomerular filtration rate (eGFR) 12 months after initiating tofogliflozin (20 mg) and their corresponding baseline values in 130 patients with type 2 diabetes. The subjects were divided into two groups: normal (≥60 mL/min/1.
JMA J
October 2024
Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Introduction: Long hospital stay is associated with high costs and poor quality of life in elderly patients with heart failure (HF). This study aimed to investigate the association of early administration of tolvaptan with length of hospital stay among elderly patients with HF.
Methods: The cohort included elderly patients (age ≥ 75 years) admitted to Shinonoi General Hospital between July 2016 and December 2018 with a primary diagnosis of acute decompensated HF treated with tolvaptan.
Circ Cardiovasc Interv
November 2024
Duke Clinical Research Institute (D.M.W., C.B.G., J.H.A., R.D.L.), Duke University, Durham, NC.
Background: In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), the combination of dual antiplatelet therapy plus oral anticoagulation increased the risk of bleeding without reducing ischemic events compared with a P2Y12 inhibitor plus oral anticoagulation among patients with atrial fibrillation and acute coronary syndrome or elective percutaneous coronary intervention. However, AUGUSTUS enrolled patients up to 14 days after acute coronary syndrome or percutaneous coronary intervention, and there may be a benefit to dual antiplatelet therapy plus oral anticoagulation early after an ischemic event.
Methods: In this secondary analysis of AUGUSTUS, we divided patients into groups based on whether they were enrolled <6 days (early) or ≥6 days (later) after their index acute coronary syndrome or percutaneous coronary intervention, and tested the interaction between time from the index event to enrollment and randomized treatment (apixaban versus vitamin K antagonist and aspirin versus placebo) on 30-day and 6-month clinical outcomes using Cox proportional hazards models.
Circulation
December 2024
Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark (C.H., R.P.B., T.E., L.H., J.E.M.).
Background: In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.
Methods: In this international, randomized, open-label, multicenter trial, 355 adult patients with ST-segment-elevation myocardial infarction-related cardiogenic shock were randomized to mAFP (n=179) or standard care alone (n=176).
Heart Rhythm
October 2024
Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland. Electronic address:
Background: Cardiac resynchronization therapy (CRT) is a cornerstone in the treatment of selected heart failure patients. However, a relevant proportion of patients do not show beneficial response. Identification of simple, additive, and outcome-relevant selection criteria may improve selection of patients.
View Article and Find Full Text PDFNutrients
September 2024
Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Breast Cancer
January 2025
Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
JAMA Neurol
September 2024
Department of Cardiology, Sint Antonius Ziekenhuis, Nieuwegein, the Netherlands.
Circ Cardiovasc Qual Outcomes
October 2024
Department of Medicine, Stanford University School of Medicine, CA (F.R., D.J.M.).
Background: The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) demonstrated greater health status benefits with an initial invasive strategy, as compared with a conservative one, for patients with chronic coronary disease and moderate or severe ischemia. Whether these benefits vary globally is important to understand to support global adoption of the results.
Methods: We analyzed participants' disease-specific health status using the validated 7-item Seattle Angina Questionnaire (SAQ: >5-point differences are clinically important) at baseline and over 1-year follow-up across 37 countries in 6 international regions.
Nat Med
November 2024
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II-III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P < 0.
View Article and Find Full Text PDFCells
August 2024
Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Hypertens Res
November 2024
Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, Japan.
Bilateral renal denervation (RDN) decreases arterial pressure (AP) or delays the development of hypertension in spontaneously hypertensive rats (SHR), but whether bilateral RDN significantly modifies urine output function during baroreflex-mediated acute AP changes remains unknown. We quantified the relationship between AP and normalized urine flow (nUF) in SHR that underwent bilateral RDN (n = 9) and compared the results with those in sham-operated SHR (n = 9). Moreover, we examined the acute effect of an angiotensin II type 1 receptor blocker telmisartan (2.
View Article and Find Full Text PDFLancet
September 2024
Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:
Background: Dual antiplatelet therapy (DAPT) for 12 months is the standard of care after coronary stenting in patients with acute coronary syndrome (ACS). The aim of this individual patient-level meta-analysis was to summarise the evidence comparing DAPT de-escalation to ticagrelor monotherapy versus continuing DAPT for 12 months after coronary drug-eluting stent implantation.
Methods: A systematic review and individual patient data (IPD)-level meta-analysis of randomised trials with centrally adjudicated endpoints was performed to evaluate the comparative efficacy and safety of ticagrelor monotherapy (90 mg twice a day) after short-term DAPT (from 2 weeks to 3 months) versus 12-month DAPT in patients undergoing percutaneous coronary intervention with a coronary drug-eluting stent.
J Cardiol
August 2024
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan.
Am J Sports Med
September 2024
Department of Orthopaedic Surgery, Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA.
Circ Heart Fail
October 2024
Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium (F.H.V.).
J Am Coll Cardiol
August 2024
Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address:
Transcatheter aortic valve (TAV) thrombosis may manifest as subclinical leaflet thrombosis (SLT) and clinical valve thrombosis. SLT is relatively common (10%-20%) after transcatheter aortic valve replacement, but clinical implications are uncertain. Clinical valve thrombosis is rare (1.
View Article and Find Full Text PDFCirc Rep
August 2024
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital Kobe Japan.
J Atheroscler Thromb
November 2024
Department of Cardiovascular Medicine, Shinshu University Hospital.
Lipid-lowering therapy plays a central role in reducing cardiovascular events. Over the past few decades, clinical trials utilizing several imaging techniques have consistently shown that lipid-lowering therapy can reduce the coronary plaque burden and improve plaque composition. Although intravascular ultrasound has been the most extensively used modality to assess plaque burden, other invasive modalities, such as optical coherence tomography and near-infrared spectroscopy, provide relevant data on plaque vulnerability, and computed tomography angiography detects both plaque volume and characteristics non-invasively.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
December 2024
Division of Vascular and Interventional Radiology, Medical University of South Carolina, Charleston, SC, USA.
Benign central venous occlusions are frequently associated with long-term central venous access. Most of these occlusions can be recanalized with conventional endovascular technique. When conventional technique fails, sharp recanalization techniques (SRTs) can increase technical success.
View Article and Find Full Text PDF